Paul D. Burgess - 03 Jul 2023 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role
Title: Chief Business Development and Strategic Operations Officer
Signature
/s/ Scott Akamine, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
03 Jul 2023
Net transactions value
$0
Form type
4
Filing time
06 Jul 2023, 16:16:25 UTC
Previous filing
28 Jun 2023
Next filing
07 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERE Stock Option (Right to Buy) Award $0 +95,931 $0.000000 95,931 03 Jul 2023 Common Stock 95,931 $31.45 Direct F1
transaction CERE Restricted Stock Units Award $0 +23,847 $0.000000 23,847 03 Jul 2023 Common Stock 23,847 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on July 3, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2 The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of July 3, 2024, July 3, 2025, July 3, 2026 and July 3, 2027, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Title: Chief Business Development and Strategic Operations Officer